COMMISSION IMPLEMENTING REGULATION (EU) 2015/2085
of 18 November 2015
approving the active substance mandestrobin, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
(Text with EEA relevance)
Article 1
Approval of active substance
Article 2
Amendments to Implementing Regulation (EU) No 540/2011
Article 3
Entry into force
ANNEX I
Common Name, Identification Numbers |
IUPAC Name |
Purity(1) |
Date of approval |
Expiration of approval |
Specific provisions |
||||||||
Mandestrobin CAS No: 173662-97-0 CIPAC No: Not available |
(RS)-2-methoxy-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide |
≥ 940 g/kg (on a dry weight basis) Xylenes (ortho, meta, para), ethyl benzene max. 5 g/kg (TK) |
9 December 2015 |
9 December 2025 |
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on mandestrobin, and in particular Appendices I and II thereof, shall be taken into account. In this overall assessment Member States shall pay particular attention to:
Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit confirmatory information as regards:
The applicant shall submit that information to the Commission, the Member States and the Authority by 9 June 2016. |
ANNEX II
|
Common Name, Identification Numbers |
IUPAC Name |
Purity(1) |
Date of approval |
Expiration of approval |
Specific provisions |
||||||||
‘93 |
Mandestrobin CAS No: 173662-97-0 CIPAC No: Not available |
(RS)-2-methoxy-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide |
≥ 940 g/kg (on a dry weight basis) Xylenes (ortho, meta, para), ethyl benzene max. 5 g/kg (TK) |
9 December 2015 |
9 December 2025 |
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on mandestrobin, and in particular Appendices I and II thereof, shall be taken into account. In this overall assessment Member States shall pay particular attention to:
Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit confirmatory information as regards:
The applicant shall submit that information to the Commission, the Member States and the Authority by 9 June 2016.’ |